1. Home
  2. DRUG

DRUG

Bright Minds Biosciences Inc.

Logo Bright Minds Biosciences Inc.

Health Care

Pharmaceuticals and Biotechnology

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Founded: 2019 Country:
Canada
Canada
Employees: N/A City: N/A
Market Cap: 5.7M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 25.3K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.30 EPS Growth: N/A
52 Week Low/High: $1.09 - $6.44 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: